Date of download: 6/3/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Efficacy of Low-Release-Rate Fluocinolone Acetonide Intravitreal Implants to Treat Experimental Uveitis Arch Ophthalmol. 2006;124(7): doi: /archopht Cumulative in vitro release profile of the 0.5-mg sustained-release fluocinolone acetonide implant (white squares) and the 0.1-mg implant (black circles) throughout 10 days. Values represent mean±SD (error bars). The release rate is 0.67 ± 0.12 μg/d for the 0.5- mg sustained-release fluocinolone implant and 0.08 ± 0.04 μg/d for the 0.1-mg sustained-release fluocinolone implant. Figure Legend:

Date of download: 6/3/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Efficacy of Low-Release-Rate Fluocinolone Acetonide Intravitreal Implants to Treat Experimental Uveitis Arch Ophthalmol. 2006;124(7): doi: /archopht Clinical grade of anterior chamber (AC) cells (A), flare (B), and vitreous opacity (C) at different times after intravitreal challenge. Median grades plus 75th percentile (positive error bars) or 25th percentile (negative error bars) are illustrated for the control group (top row), the 0.1-μg/d sustained-release fluocinolone acetonide implant (second row), and the 0.5-μg/d sustained-release fluocinolone acetonide intravitreal implant (third row). The third row illustrates median grades of the control group compared with both implant groups. Figure Legend:

Date of download: 6/3/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Efficacy of Low-Release-Rate Fluocinolone Acetonide Intravitreal Implants to Treat Experimental Uveitis Arch Ophthalmol. 2006;124(7): doi: /archopht Ratio of b-wave amplitudes (antigen-challenged eye to fellow eye) at day 6 after intravitreal challenge. Values represent mean±SD (error bars). Figure Legend:

Date of download: 6/3/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Efficacy of Low-Release-Rate Fluocinolone Acetonide Intravitreal Implants to Treat Experimental Uveitis Arch Ophthalmol. 2006;124(7): doi: /archopht Quantitative measurement of aqueous leukocytes (A) and aqueous protein (B) at day 6 after intravitreal challenge. Values represent mean ± SD (error bars). P values overlying 0.1- and 0.5-μg/d data represent 2-tailed comparison with the untreated group. Figure Legend:

Date of download: 6/3/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Efficacy of Low-Release-Rate Fluocinolone Acetonide Intravitreal Implants to Treat Experimental Uveitis Arch Ophthalmol. 2006;124(7): doi: /archopht Hematoxylin-eosin–stained sections of study eyes at day 6 after intravitreal challenge. Row 1, Control eye. A, Iris and ciliary body processes with inflammatory cell infiltrates seen in the peripheral corneal stroma, limbus, and anterior chamber angle (original magnification ×2.5). B, The ciliary body process was markedly swollen with proteinaceous exudates and surrounded by inflammatory cell infiltrates (original magnification ×10). C, Retinal cross section with proteinaceous vitreous and inflammatory cells infiltrating the vitreous, retina, and choroid (original magnification ×40). No subretinal fluid was seen, but a detachment artifact was present. Row 2, Eye implanted with a 0.1-μg/d sustained-release fluocinolone acetonide implant. D, Iris and ciliary body processes (original magnification ×2.5). E, Ciliary body process (original magnification ×10). F, Retinal cross section with rare vitreous and superficial retinal inflammatory cell infiltrate but overall preserved architecture (original magnification ×40). Row 3, Eye implanted with a 0.5-μg/d sustained-release fluocinolone acetonide implant. G, Iris and ciliary body processes (original magnification ×2.5). H, Ciliary body process (original magnification ×10). I, Retinal cross section with normal architecture (original magnification ×40). Figure Legend: